Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy

[1]  J. Kochenderfer,et al.  A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains , 2021, Nature Reviews Clinical Oncology.

[2]  Q. Qian,et al.  Current Progress in CAR-T Cell Therapy for Hematological Malignancies , 2021, Journal of Cancer.

[3]  R. Kiessling,et al.  Counteracting CAR T cell dysfunction , 2020, Oncogene.

[4]  G. Coukos,et al.  Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression , 2020, The Journal of experimental medicine.

[5]  R. Heller,et al.  IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models , 2021, Frontiers in Immunology.

[6]  C. Turtle,et al.  Cytokines in CAR T Cell–Associated Neurotoxicity , 2020, Frontiers in Immunology.

[7]  P. Dreger,et al.  Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  F. Marincola,et al.  Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy , 2020, Journal for ImmunoTherapy of Cancer.

[9]  M. Maus,et al.  Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. , 2020, Annual review of medicine.

[10]  L. Kats,et al.  IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  B. Sun,et al.  The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice , 2020, Frontiers in Oncology.

[12]  Jiang F Zhong,et al.  Recent advances in CAR-T cell engineering , 2020, Journal of Hematology & Oncology.

[13]  C. Mackall,et al.  The Emerging Landscape of Immune Cell Therapies , 2020, Cell.

[14]  A. Ducruet,et al.  IL (Interleukin)-15 Bridges Astrocyte-Microglia Crosstalk and Exacerbates Brain Injury Following Intracerebral Hemorrhage , 2020, Stroke.

[15]  R. Shaik,et al.  Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma , 2020, Cancer Immunology Research.

[16]  J. Leroux,et al.  Opposing roles of endothelial and leukocyte-expressed IL-7Rα in the regulation of psoriasis-like skin inflammation , 2019, Scientific Reports.

[17]  Alaina Kaiser,et al.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. , 2018, Blood.

[18]  E. Sherwood,et al.  Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. , 2017, Cytokine & growth factor reviews.

[19]  Hao Liu,et al.  Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants , 2017, Cancer Immunology Research.

[20]  J. Friedberg,et al.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Schunkert,et al.  Applications and Limitations of Mouse Models for Understanding Human Atherosclerosis. , 2017, Cell metabolism.

[22]  L. Hurton,et al.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells , 2016, Proceedings of the National Academy of Sciences.

[23]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[24]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[25]  D. Pardoll,et al.  Therapeutic administration of IL‐15 superagonist complex ALT‐803 leads to long‐term survival and durable antitumor immune response in a murine glioblastoma model , 2016, International journal of cancer.

[26]  Julián Pardo,et al.  How Do Cytotoxic Lymphocytes Kill Cancer Cells? , 2015, Clinical Cancer Research.

[27]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Schmitt-Graeff,et al.  Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD. , 2015, Blood.

[29]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[31]  H. Wong,et al.  The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity , 2013, Oncoimmunology.

[32]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[33]  J. Prieto,et al.  Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. , 2013, Cancer research.

[34]  H. Staats,et al.  Cytokines: The Future of Intranasal Vaccine Adjuvants , 2011, Clinical & developmental immunology.

[35]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[36]  J. Gołąb,et al.  Interleukin 15 as a promising candidate for tumor immunotherapy. , 2011, Cytokine & growth factor reviews.

[37]  A. Bessard,et al.  High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer , 2009, Molecular Cancer Therapeutics.

[38]  Chien-Fu Hung,et al.  Expression of IL‐15RA or an IL‐15/IL‐15RA fusion on CD8+ T cells modifies adoptively transferred T‐cell function in cis , 2009, European journal of immunology.

[39]  T. Waldmann,et al.  Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action1 , 2008, The Journal of Immunology.

[40]  T. Waldmann,et al.  The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells , 2007, Proceedings of the National Academy of Sciences.

[41]  J. Sprent,et al.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Park,et al.  Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex , 1996, Journal of Clinical Immunology.

[43]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[44]  P. Burkett,et al.  Regulation of lymphoid homeostasis by interleukin-15. , 2002, Cytokine & growth factor reviews.

[45]  D. Busch,et al.  Overexpression of IL-15 In Vivo Increases Antigen-Driven Memory CD8+ T Cells Following a Microbe Exposure1 , 2002, The Journal of Immunology.

[46]  C. Seager.  Therapies , 1973, Journal of the Neurological Sciences.

[47]  Kirk W. Johnson,et al.  The Circulating Common Gamma Chain (CD132) in Inflammatory Bowel Disease , 1998, American Journal of Gastroenterology.

[48]  D. Cosman,et al.  Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15. , 1994, The EMBO journal.

[49]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.